Consun Pharmaceutical Group Ltd.

As of December 31, 2025, Consun Pharmaceutical Group Ltd. carries a market capitalization of 13.14B, placing it among publicly traded companies globally. Its enterprise value stands at 9.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Consun Pharmaceutical Group Ltd.'s next confirmed earnings release is scheduled for March 24, 2027.

As of December 31, 2025, Consun Pharmaceutical Group Ltd. has 840.11M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Consun Pharmaceutical Group Ltd. maintains a current ratio of 3.22, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 23, 2026, Consun Pharmaceutical Group Ltd.'s stock has gained approximately 2.67% over the past 52 weeks. The 50-day moving average sits at 14.14, while the 200-day moving average is 15.22.

As of December 31, 2025, Consun Pharmaceutical Group Ltd. holds 4.34B in cash and equivalents against 236.96M in total debt, resulting in a net debt position of -1.15B. Total book value stands at 5.05B, with working capital of 3.53B providing operational flexibility.